In this issue:
Etrolizumab vs. infliximab for moderately to severely active UC
Impact of anti-infliximab antibodies on clearance and response in paediatric CD
Tofacitinib for UC
Impact of IBD and its medications on COVID-19
Flexible sigmoidoscopy for initial evaluation of suspected immunotherapy-mediated colitis
Dietary gluten does not increase IBD risk in the absence of coeliac disease
Serious infection risk with vedolizumab vs. anti-TNF agents in IBD
Remote therapeutic drug monitoring in IBD
T-cell response after SARS-COV-2 vaccination in immunocompromised patients with IBD
Ultra-proactive infliximab therapeutic drug monitoring in IBD
Please login below to download this issue (PDF)